Description
Sertraline exhibits antidepressant and anxiolytic activities; it is a typical selective serotonin reuptake inhibitor (SSRI). Sertraline primarily inhibits the 5-HT transporter (SERT), but also inhibits the dopamine transporter (DAT), α1-adrenergic receptors, and potentially σ1 receptors. Additionally, sertraline inhibits osteoclast formation and resorption and induces apoptosis in both osteoclasts and osteoblasts. This compound also acts as a functional inhibitor of acid sphingomyelinase (FIASMA).
References
Guaiana G, Gupta S, Chiodo D, et al. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013 Dec 17;12:CD008851. PMID: 24343836.
Zhu H, Bogdanov MB, Boyle SH, et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One. 2013 Jul 17;8(7):e68283. PMID: 23874572.
Hodge JM, Wang Y, Berk M, et al. Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry. 2013 Jul 1;74(1):32-9. PMID: 23260229.
Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004 May;161(5):826-35. PMID: 15121647.
